A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: A Southwest Oncology Group Study

Urologic Oncology: Seminars and Original Investigations

Volumn 23, Issue 6, 2005, Pages 386-389

  Sarosdy, Michael F ^a   Tangen, Catherine M ^b   Weiss, Geoffrey R ^c   Nestok, Blake R ^d   Benson, Mitchell C ^e   Schellhammer, Paul F ^e   Sagalowsky, Arthur I ^f   Wood Jr , David P ^g   Crawford, E David ^h  

^a South Texas Urology and Urologic Oncology   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e Columbia Presbyterian UCOP ^*  (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF COLORADO   (United States)

Author keywords

Bladder cancer; Bropirimine; Immunotherapy

Indexed keywords

BCG VACCINE; BROPIRIMINE;

ARTICLE; BIOPSY; BLADDER DISEASE; CARCINOMA IN SITU; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYSTOSCOPY; CYTOLOGY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; FATIGUE; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LETHARGY; MAJOR CLINICAL STUDY; MALAISE; MEDICAL RECORD; MULTICENTER STUDY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THORAX PAIN; TIME SERIES ANALYSIS; URINARY FREQUENCY; URINARY URGENCY;

AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CYTOSINE; DISEASE PROGRESSION; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; SURVIVAL RATE; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 27844432612     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.05.028     Document Type: Article

References (15)

1. D.L. Lamm, B.A. Blumenstein, E.D. Crawford A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder N Engl J Med 325 1991 1205 1209
2. A. Morales, J.C. Nickel, J.W.L. Wilson Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer J Urol 147 1992 1256 1258
3. R.B. Nadler, W.J. Catalona, M.A. Hudson Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy J Urol 152 1994 367 373
4. W. Wierenga Antiviral and other bioactivities of pyrimidinones Pharmacol Ther 30 1985 67 89
5. E. Lotzova, D.S. Savary, A. Khan Stimulation of natural killer cells in two random-bred strains of athymic mice by interferon-inducing pyrimidinones J Immunol 132 1984 2566 2570
6. M.F. Sarosdy, D.L. Lamm, R.D. Williams Phase I trial of oral bropirimine in superficial bladder cancer J Urol 147 1992 31 33
7. M.F. Sarosdy, B.A. Lowe, P.F. Schellhammer Oral bropirimine immunotherapy of carcinoma in situ of the bladder Results of a phase II trial Urology 48 1996 21 27
8. M.F. Sarosdy, L.L. Pisters, P.R. Carroll Bropirimine immunotherapy of upper urinary tract carcinoma in situ Urology 48 1996 28 32
9. M.F. Sarosdy, C.A. Kierum Combination immunotherapy of murine transitional cell carcinoma using BCG and an interferon-inducing pyrimidinone J Urol 142 1989 1376 1379
10. D.L. Lamm, B.A. Blumenstein, J.D. Crissman Maintenance BCG immunotherapy in recurrent TA, T1 and carcinoma in situ transitional cell carcinoma A Randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129
11. R. Glashan A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder J Urol 144 1990 658 661
12. R.D. Williams, D.M. Gleason, A.Y. Smith Pilot study of intravesical alfa-2b interferon for treatment of bladder carcinoma in situ following BCG failure J Urol 155 1996 494A
13. T.T. Bui, P.F. Schellhammer Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response Urology 49 1997 687 690
14. M.J. Manayak Photodynamic therapy for urologic malignancies Urol Clin North Am 19 1992 581 589
15. A.L. Patterson, R.E. Greenberg, L. Weems Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer Urology 56 2000 232 235